For medical information, general AI frontier models (Google, OpenAI, Anthropic) outperformed specialized @EvidenceOpen and @UpToDate as assessed by 12 US clinicians, randomized and blinded to which model and extensive testing/benchmarks. This was not anticipated. @NatureMedicine nature.com/articles/s41591-0…

En IgA proteinurica, añadir atresantan, comparado a placebo; evito la pérdida de TFGe 2.6ml/min y ↓26% proteinuria a 2.5 años. Mejor aún si se combina con iSGLT2. Además de ser aceptablemente tolerado Ensayo clínico ALIGN The Lancet 2026 doi.org/10.1016/S0140-6736(2…

🎉 El #CLÍNIC alcanza los 1️⃣0️⃣0️⃣ pacientes en #DiálisisDomiciliaria . Con una verdadera cultura pro🏠, un equipo comprometido y apoyo institucional, es posible. Queda mucho camino por recorrer, pero hoy toca celebrarlo. @elenc93 @b_galceran @nurietaCle @FMaduell @30965rrs

La actualización de las guías #KDIGO 2026 sobre #anemia en la #ERC introduce cambios relevantes, pero también plantea interrogantes. En el Grupo de Anemia de la @SENefrologia realizamos una lectura crítica y adaptada al contexto español. 📖sciencedirect.com/science/ar…

🧵 Symposium: Non-pharmacological approaches to cardiovascular complications in CKD #ERA26 🎙️Chaired by Jonathan Gabriel Fox & Milica Bozic 🫀Cardiovascular disease (#CVD) remains the leading cause of morbidity and mortality across the #CKD spectrum. 🟢Beyond💊: exercise, diet and the microbiome as CV therapies in CKD Today’s speakers will discuss: 👟Exercise training and cardiovascular disease in severe CKD — Naomi Clyne 🧂 Sodium and potassium: the yin and yang of hypertensive vascular disease — Johannes Stegbauer 🦠 The gut microbiome and cardiovascular burden in CKD — Laetitia Koppe Follow this thread for key insights 👇

🧵 Free Communications 18: Bones, Hearts & Metabolism: Dialysis Complications Unpacked #ERA26 Chaired by Jovana Kusic Milicevic and Pieter Evenepoel. Today’s session explores key complications in hemodialysis: 🩸 Bleeding risk and anticoagulation 🦴 Osteoporosis and fractures ❤️ Cardiovascular risk prediction 🏃 Exercise-based cardioprotection Follow this thread for the key findings 👇

#ERA2026 💡Interesting work comparing HV-HDF and HDx using different β2-microglobulin clearance metrics. ✅As expected, HV-HDF achieved higher β2M clearance. ✅The novel aspect was the evaluation of eCDCβ2M, an equivalent continuous clearance metric that may better reflect middle-molecule kinetics than traditional reduction ratios or urea-derived measures. The next challenge: proving that these metrics predict clinical outcomes, not just toxin removal. #Nephrology #Dialysis #HDF #HDx

#ERA2026 39,750 patients. 583,457 HDF sessions. 🏋️ Lean tissue mass → higher substitution volume 🫃 Fat tissue mass → no independent association 💡Perhaps it's time to move beyond body size and consider body composition when evaluating and comparing convective dose delivery in HDF. #Nephrology #Dialysis #HDF #BodyComposition

Deciding between conservative kidney management and dialysis in older people with kidney failure: a narrative review doi.org/10.1093/ckj/sfag183

🧵 Symposium: Multiple health conditions (multimorbidity) in CKD #ERA26 🎙️Moderated by Patrick Mark and Siren Sezer. #Multimorbidity affects most people living with #CKD and has major implications for prognosis, risk prediction and patient-centred care. Today’s speakers: 🧓🏻Multimorbidity in older adults with CKD - Giorgi Beridze 📊Dialysis risk prediction in complex patients - Heather Walker 🧠Mental health in CKD - Kenneth Farrington Follow this thread for the key insights 👇

Sodium Glucose Cotransporter 2 Inhibitors in Kidney Transplant Recipients | #ERA26 Non Diabetic Recipients: Barcelona cohort showed sodium glucose cotransporter 2 inhibitor initiation led to significant proteinuria reduction and estimated glomerular filtration rate stabilization in non diabetic kidney transplant recipients. A dedicated double blind placebo controlled randomized controlled trial is now recruiting. Mechanisms Beyond Glucose: Reduced intraglomerular pressure and natriuresis via tubuloglomerular feedback Anti fibrotic effects via transforming growth factor beta mediated suppression and reduced tubular stress May act as pharmacological reinnervation after kidney transplantation due to ischemia reperfusion injury and loss of sympathetic innervation Ongoing Trials: SGL-TX-GFR: 88 non diabetic recipients with estimated glomerular filtration rate greater than 25, testing 10 milligram dapagliflozin versus placebo for 18 months. Outcomes include graft function, safety, urinary tract infections, post transplant diabetes, albuminuria RENAISSANCE: 900 adult recipients 6 months post transplant. Tests if sodium glucose cotransporter 2 inhibitor reduces death, graft loss, major cardiovascular events, and estimated glomerular filtration rate decline RENAL LIFECYCLE: Includes kidney transplant recipients with estimated glomerular filtration rate less than or equal to 45. Expectation is reduction in all cause mortality, renal failure, and heart failure hospitalizations with and without type 2 diabetes Meta-Analysis: 32 studies with 7834 kidney transplant recipients showed sodium glucose cotransporter 2 inhibitors and glucagon like peptide 1 receptor agonists associated with improved survival, cardiovascular, and kidney outcomes with favorable safety profile. Safety and Use: Current observational, real world, and randomized controlled trial data do not suggest excess risk post transplant. Safety signals need vigilance. While awaiting definitive randomized controlled trial data, pragmatic adoption in select high risk groups is encouraged. Takeaway: Sodium glucose cotransporter 2 inhibitors have strong biological rationale and emerging data for graft and cardiovascular protection in kidney transplant recipients, including non diabetic patients. Presentation: Adnan Sharif | Tweet: @eroldemir83

simultaneous publication during #ERA26

Kidney disease (CKD) and heart failure (HFrEF, HFpEF): recent advances and current challenges: conclusions from @goKDIGO Controversies Conference ca. 2026 from @Kidney_Int #Nephpearls #Cardiorenal 👉 pubmed.ncbi.nlm.nih.gov/4179…

Obesity in CKD: Core Curriculum 2026 ajkd.org/article/S0272-6386%…

Chloride at the spotlight—but not alone: toward a multi-ionic diuretic strategy doi.org/10.1093/ckj/sfag119